Keijirio Saku

Prof. Dr. Keijirio Saku


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Circulation Journal
Verified
Journal Article
Closed access
KSKeijirio Saku
Keijirio Saku
BZBo Zhang
Bo Zhang
KNKeita Noda
Keita Noda
TIThe PATROL Trial Investigators
The PATROL Trial Investigators
Atorvastatin, rosuvastatin and pitavastatin are available for intensive, aggressive low-density lipoprotein cholesterol (LDL-C)-lowering therapy in clinical practice. The objective of the Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL) (PATROL) Trial was to compare the safety and efficacy of atorvastatin, rosuvastatin and pitavastatin head to head in patients with hypercholesterolemia. This is the first prospective randomized multi-center trial to compare these strong statins (UMIN Registration No: 000000586). Patients with risk factors for coronary artery disease and elevated LDL-C levels were randomized to receive atorvastatin (10mg/day), rosuvastatin (2.5mg/day), or pitavastatin (2mg/day) for 16 weeks. Safety was assessed in terms of adverse event rates, including abnormal clinical laboratory variables related to liver and kidney function and skeletal muscle. Efficacy was assessed by the changes in the levels and patterns of lipoproteins. Three hundred and two patients (from 51 centers) were enrolled, and these 3 strong statins equally reduced LDL-C and LDL particles, as well as fast-migrating LDL (modified LDL) by 40-45%. Newly developed pitavastatin was non-inferior to the other 2 statins in lowering LDL-C. There were no differences in the rate of adverse drug reactions among the 3 groups, but HbA(1c) was increased while uric acid was decreased in the atorvastatin and rosuvastatin groups. The safety and efficacy of these 3 strong statins are equal. It is suggested that the use of these 3 statins be completely dependent on physician discretion based on patient background.

1 January 2014 in Circulation Journal
Verified
Journal Article
Open access
PDF file
KTKohei Takata
Kohei Takata
SISatoshi Imaizumi
Satoshi Imaizumi
EKEmi Kawachi
Emi Kawachi
YSYasunori Suematsu
Yasunori Suematsu
TSTomohiko Shimizu
Tomohiko Shimizu
KSKeijirio Saku
Keijirio Saku
Background:Smoking cessation reduces the risk of cardiovascular disease (CVD) and improves clinical outcomes in public health. We studied the effect of smoking cessation on high-density lipoprotein (HDL) functionality.Methods and Results:We randomly treated 32 smokers with varenicline or a transdermal nicotine patch as part of a 12-week smoking cessation program (The VN-SEESAW Study). The plasma lipid profiles, plasma and HDL malondialdehyde (MDA) levels, HDL subfractions as analyzed by capillary isotachophoresis, cholesterol efflux capacity, and antiinflammatory activity of HDL were measured before and after the anti-smoking intervention. After smoking cessation, HDL-C, apoA-I levels and HDL subfractions were not significantly different from the respective baseline values. However, cholesterol efflux capacity and the HDL inflammatory index (HII) were significantly improved after smoking cessation. The changes in both parameters (%∆ cholesterol efflux capacity and ∆HII) were also significantly improved in the successful smoking cessation group compared with the unsuccessful group. The changes in cholesterol efflux capacity and HII also correlated with those in end-expiratory CO concentration and MDA in HDL, respectively.Conclusions:Our findings indicate that smoking cessation leads to improved HDL functionality, increased cholesterol efflux capacity and decreased HII, without changing HDL-C or apoA-I levels or HDL subfractions. This may be one of the mechanisms by which smoking cessation improves the risk of CVD. (Circ J 2014; 78: 2955–2962)

20 May 2013 in Journal of the American Heart Association
Verified
Journal Article
Open access
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
SASetsuko Ando
Setsuko Ando
EYEiji Yahiro
Eiji Yahiro
KOKosuke Oniki
Kosuke Oniki
MAMakoto Ayaori
Makoto Ayaori
KSKeijirio Saku
Keijirio Saku
Background: Apolipoprotein (apo) A‐I is a major high‐density lipoprotein ( HDL ) protein that causes cholesterol efflux from peripheral cells through the ATP ‐binding cassette transporter A1 ( ABCA 1), thus generating HDL and reversing the macrophage foam cell phenotype. Pre‐β 1 HDL is the smallest subfraction of HDL , which is believed to represent newly formed HDL , and it is the most active acceptor of free cholesterol. Furthermore it has a possible protective function against cardiovascular disease ( CVD ). We developed a novel apoA‐I mimetic peptide without phospholipids (Fukuoka University ApoA‐I Mimetic Peptide, FAMP ). Methods and Results: FAMP type 5 ( FAMP 5) had a high capacity for cholesterol efflux from A172 cells and mouse and human macrophages in vitro, and the efflux was mainly dependent on ABCA 1 transporter. Incubation of FAMP 5 with human HDL or whole plasma generated small HDL particles, and charged apoA‐I‐rich particles migrated as pre‐β HDL on agarose gel electrophoresis. Sixteen weeks of treatment with FAMP 5 significantly suppressed aortic plaque formation (scrambled FAMP , 31.3±8.9% versus high‐dose FAMP 5, 16.2±5.0%; P <0.01) and plasma C‐reactive protein and monocyte chemoattractant protein‐1 in apoE‐deficient mice fed a high‐fat diet. In addition, it significantly enhanced HDL ‐mediated cholesterol efflux capacity from the mice. Conclusions: A newly developed apoA‐I mimetic peptide, FAMP , has an antiatherosclerotic effect through the enhancement of the biological function of HDL . FAMP may have significant atheroprotective potential and prove to be a new therapeutic tool for CVD .

1 September 2009 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
BZBo Zhang
Bo Zhang
AMAkira Matsunaga
Akira Matsunaga
DRDavid L. Rainwater
David L. Rainwater
SMShin-Ichiro Miura
Shin-Ichiro Miura
KNKeita Noda
Keita Noda
KSKeijirio Saku
Keijirio Saku
Bo Zhang, Akira Matsunaga, David L. Rainwater, Shin-ichiro Miura, Keita Noda, Hiroaki Nishikawa, Yoshinari Uehara, Kazuyuki Shirai, Masahiro Ogawa, Keijiro Saku

1 June 2005 in Current Hypertension Reviews
Verified
Journal Article
Closed access
PDF file
SMShin-Ichiro Miura
Shin-Ichiro Miura
MFMasahiro Fujino
Masahiro Fujino
KSKeijirio Saku
Keijirio Saku
Angiotensin II (Ang II) receptor blockers (ARBs) are highly selective for the Ang II type 1 receptor (AT1), which is a member of the G protein-coupled receptor superfamily (GPCRs), and block the diverse effects of the agonist Ang II. Many studies have shown that these agents are safe and effective. In addition to their beneficial effects against hypertension, ARBs have also been associated with the regression of left ventricular hypertrophy and a decrease in cardiovascular morbidity and mortality in patients with heart failure or hypertensive diabetic nephropathy with proteinuria. Many ARBs are available for clinical use. Since ARBs do not all have the same effects, the benefits conferred by ARBs may not be class effects. Over the past decade it has become possible to detect agonist-independent signal transduction by GPCRs, and ligands described as inverse agonists, which can block activities, have been described. One type of ARB has been shown to have inverse agonistic action in an in vitro mutagenesis study. In addition, mechanical stretch-induced signals through AT 1 receptor have been shown to be independent of Ang II stimulation, and these signals are blocked by an ARB. These findings represent an exciting new area in ARB treatment. ARB-based therapy holds the promise of reducing the incidence of cardiovascular disease. This review will address the roles of inverse agonistic action and its blockade in the cardiovascular system.

1 January 2012 in Circulation Journal
Verified
Journal Article
Open access
PDF file
RKRie Koyoshi
Rie Koyoshi
SMShin-ichiro Miura
Shin-ichiro Miura
NKNaoko Kumagai
Naoko Kumagai
YSYuhei Shiga
Yuhei Shiga
RMRyoko Mitsutake
Ryoko Mitsutake
KSKeijirio Saku
Keijirio Saku
Background: Little is known about the interrelationships among brachial flow-mediated vasodilatation (bFMD), brachial-ankle pulse wave velocity (baPWV) and brachial intima-media thickness (bIMT) in patients with and without coronary artery disease (CAD). Methods and Results: Two-hundred consecutive patients with stable angina pectoris (SAP) were enrolled as the CAD group and 50 age-, sex- and body mass index-matched patients without CAD were selected as the non-CAD group. bFMD, diastolic blood pressure (DBP) and high-density lipoprotein cholesterol (HDL-C) in the CAD group were significantly lower. The CAD group showed significantly higher levels of hemoglobin A1c (HbA1c) and low-density lipoprotein cholesterol (LDL-C), but not baPWV. CAD was independently associated with bFMD, DBP, HbA1c and HDL-C. bFMD and HDL-C significantly decreased and LDL-C increased as the number of diseased vessels with significant stenosis increased. The number of diseased vessels was independently associated with bFMD and HDL-C. In addition, bFMD, bIMT, the time constant of the shear rate and the time constant of the flow rate as assessed by a new program, Trend Plus®, were associated with the presence of CAD. Among these parameters, the presence of CAD was independently associated with bIMT as well as bFMD. Conclusions: bFMD was a better predictor of the severity of CAD than either baPWV or coronary risk factors in patients with SAP. In addition, bIMT may be a critical predictor of CAD. (Circ J 2012; 76: 1469-1475)